Cameco enters August nursing a 16% monthly decline — the steepest correction in over a year — even as uranium's long-term demand story remains largely intact.
The stock closed July 31 at CAD 120.98, down another 2.1% on the day and 2.3% on the week. The month's damage is the real story. A P/E that has compressed from the high 60s to 54.7x and a price-to-book that has shed 1.2 points over 30 days to 6.45x reflect a genuine re-rating of the growth premium, not just noise. EV/EBITDA at 24x has barely moved over the month, suggesting the market is squeezing the earnings multiple specifically rather than rethinking the enterprise value wholesale. EPS momentum factor scores remain healthy — 78th percentile over 30 days and 72nd over 90 days — but the forward earnings growth rank has slipped to the 26th percentile, a signal that analysts have been trimming the outer-year numbers as the stock ran up. Note that all analyst price target data is stale (last updated January 2021) and cannot be used as a current reference point.
Positioning offers no friction to explain the slide — this is entirely a price story, not a short-squeeze or borrow story. Short interest is minimal at 0.74% of free float, and it has edged slightly lower over the week. Borrow costs hover near 0.60% annually, one of the cheapest rates in the lending market. Availability is effectively unlimited at 6,835% of current short interest, meaning for every share currently borrowed, there are roughly 68 more available to lend. The short score is a stable 27.5, barely moving over the past two weeks. None of the lending-market signals point to speculative pressure — bears are not building; they are simply absent.
The divergence with peers this week is modest but consistent in direction. Closely correlated TSX names NXE and DML fell 0.5% and 3.7% respectively over the week, with smaller names like SYH and URC down 5.1% and 6.7%. UEC and EFR managed marginal gains, suggesting there is some rotation within the uranium complex rather than a clean sector-wide retreat. Cameco's 2.3% weekly loss sits roughly in the middle of the peer range — neither a relative outperformer nor the worst hit. The month-long drawdown, however, is more pronounced for Cameco given the premium multiple it carries.
Institutional ownership shows no obvious capitulation. BlackRock reported a 21.9 million share holding as of June 30, a position that grew by over 17 million shares in the last reported period — a substantial addition by the sector's largest passive holder. Van Eck, a key uranium-themed ETF manager, added 651,550 shares over the same window. Recent insider activity has been limited to small VP-level sales in June, none above 300 shares and all carrying the lowest significance score. There is no indication of C-suite distribution.
The next scheduled catalyst is Q3 earnings on October 30. The one prior result with price data — the May 7 print — produced a 5.2% single-day decline and a further 8.6% over the following five trading sessions. Whether the current month's correction has pulled forward some of that earnings-risk discount is the question worth tracking between now and the October release.
See the live data behind this article on ORTEX.
Open CCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
